Literature DB >> 2282249

The epidermal growth factor receptor as a target for therapy.

A L Harris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2282249

Source DB:  PubMed          Journal:  Cancer Cells        ISSN： 1042-2196


× No keyword cloud information.
  10 in total

1.  Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.

Authors:  T Oikawa; J Hitomi; A Kono; E Kaneko; K Yamaguchi
Journal:  Int J Pancreatol       Date:  1995-08

2.  Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-alpha-mediated epidermal growth factor receptor activation.

Authors:  T Hirsch; S Eggstein; S Frank; E Farthmann; B U von Specht
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

4.  Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site.

Authors:  R Pellegrini; F Centis; S Martignone; A Mastroianni; E Tagliabue; E Tosi; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.

Authors:  J G Klijn; M P Look; H Portengen; J Alexieva-Figusch; W L van Putten; J A Foekens
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

6.  Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.

Authors:  H Modjtahedi; S A Eccles; G Box; J Styles; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun

7.  In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.

Authors:  H L McLeod; V G Brunton; N Eckardt; M J Lear; D J Robins; P Workman; M A Graham
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.

Authors:  J Kirk; J Carmichael; I J Stratford; A L Harris
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

9.  Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.

Authors:  H Modjtahedi; S Eccles; G Box; J Styles; C Dean
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.

Authors:  P Stanton; S Richards; J Reeves; M Nikolic; K Edington; L Clark; G Robertson; D Souter; R Mitchell; F J Hendler
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.